FindTrial
Sign In

Z-endoxifen

DRUG4 trials

Sponsors

QuantumLeap Healthcare Collaborative, National Cancer Institute (NCI), Atossa Therapeutics, Inc.

Conditions

AngiosarcomaBreast CancerBreast DensityBreast NeoplasmsBreast TumorsDesmoidDuctal Carcinoma in SituEarly-stage Breast Cancer

Phase 1

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
CompletedNCT01273168
National Cancer Institute (NCI)Desmoid, Gynecologic, Hormone Receptor-Positive Breast +1
Start: 2011-03-01End: 2025-12-19Updated: 2025-12-23

Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingNCT01042379
QuantumLeap Healthcare CollaborativeAngiosarcoma, Breast Cancer, Breast Neoplasms +8
Start: 2010-03-01End: 2031-12-01Target: 5000Updated: 2026-03-13
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
Active, not recruitingNCT05068388
Atossa Therapeutics, Inc.Breast Density
Start: 2021-12-21End: 2025-12-31Updated: 2024-04-26
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
RecruitingNCT06075953
QuantumLeap Healthcare CollaborativeDuctal Carcinoma in Situ
Start: 2024-02-17End: 2033-11-01Target: 400Updated: 2026-03-16

Related Papers

Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
2026-03-25
Abstract PS3-11-10: Neoadjuvant HSP90 inhibition with ganetespib significantly improves distant relapse-free survival in I-SPY2 patients with HER2-negative breast cancer with low expression of immune genes and no DNA repair deficiency
Clinical Cancer Research2026-02-17
Abstract PS1-01-09: Real-time monitoring for drug-induced interstitial lung disease with Trastuzumab Deruxtecan and Rilvegostomig combination therapy prevents persistent, symptomatic disease: Safety insights from the I-SPY2.2 platform trial
Clinical Cancer Research2026-02-17
Abstract RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial
Clinical Cancer Research2026-02-17
Abstract PS2-11-06: Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trial
Clinical Cancer Research2026-02-17
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
2025-10-24
Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
Frontiers in Oncology2025-07-24
A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images
Physics in Medicine and Biology2025-07-101 citations
Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.
2025-07-012 citations
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
Breast Cancer Research2025-06-233 citations
Abstract P2-01-23: A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC
Clinical Cancer Research2025-06-13
Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
Journal of Clinical Oncology2025-05-283 citations
Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
Journal of Clinical Oncology2025-05-28
I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
Journal of Clinical Oncology2025-05-28
Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.
Journal of Clinical Oncology2025-05-28
RECAST (Re-Evaluating Conditions for Active Surveillance Suitability as Treatment) for DCIS: Clinical trial in progress.
Journal of Clinical Oncology2025-05-28
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).
2025-05-15
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
Breast Cancer Research and Treatment2024-12-031 citations
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
2024-11-299 citations
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer.
2024-09-2710 citations

70 more papers not shown